MICHAEL LAVARNWAY: Open Payments
NPI 1700859493 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 66 payments from 9 companies in 2025. Trend: 2023 $587 · 2024 $823 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 25 | $213 |
| ABBVIE INC. | 24 | $178 |
| Braeburn Inc. | 10 | $148 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Indivior Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: REXULTI, VRAYLAR, BRIXADI, ABILIFY ASIMTUFII, AUSTEDO XR, SUBLOCADE, Auvelity, TRINTELLIX.
Industry payments across AZ — which companies pay providers there.
